Drug guidance
Lenvatinib and sorafenib for treating differentiated thyroid cancer
Condition
Cancer
Endocrine and metabolic
4 January 2022
Published on 04 Jan 2022
Last Updated on 04 Jan 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Sorafenib 200 mg tablet; and
Lenvatinib 4 mg and 10 mg capsules
for treating locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Subsidy status
Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.
Lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.
Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.
Lenvatinib and sorafenib for treating differentiated thyroid cancer (4 Jan 2022) [PDF, 120 KB]